New combo therapy aims to beat tough leukemia

NCT ID NCT07203352

Recruiting now Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a targeted drug (like dasatinib or sorafenib) to standard chemotherapy helps people with newly diagnosed acute T-lymphocytic leukemia live longer. About 154 adults will be randomly assigned to get either chemo alone or chemo plus the targeted drug. The main goal is to see if the combination improves overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: targeted drugs (dasatinib or sorafenib) plus chemotherapy
What this could lead to: If successful, this could lead to a more effective first-line treatment for acute T-lymphocytic leukemia, improving survival and reducing relapse.
What could go wrong: This is a Phase 3 trial, but results may not apply to all patients. Targeted drugs can cause side effects, and the benefit over standard chemo is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma T-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

Department of Hematology,Nanfang Hospital, Southern Medical University
RECRUITING

Guangzhou, Guangdong, 510515, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.